Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 20/20 | 0.77 |
| ▸ | PARP2 | Q9UGN5 | 16/20 | 0.77 |
| ▸ | PARP3 | Q9Y6F1 | 16/20 | 0.77 |
| ▸ | TNKS | O95271 | 2/20 | 0.61 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.61 |
| ▸ | PARP16 | Q8N5Y8 | 2/20 | 0.61 |
| ▸ | PARP4 | Q9UKK3 | 2/20 | 0.61 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.61 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.61 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.61 |
| ▸ | PARP8 | Q8N3A8 | 1/20 | 0.61 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2382839 | 0.87 | PARP1 (0.81) | PARP1PARP2PARP3TNKSPARP10 | |
| SCHEMBL2379944 | 0.87 | PARP1 (0.81) | PARP1PARP2PARP3TNKSPARP10 | |
| SCHEMBL2314408 | 0.87 | PARP1 (0.81) | PARP1PARP2PARP3TNKSPARP10 | |
| SCHEMBL2043160 | 0.87 | PARP1 (0.81) | PARP1PARP2PARP3TNKSPARP10 | |
| SCHEMBL2311187 | 0.87 | PARP1 (0.81) | PARP1PARP2PARP3TNKSPARP10 | |
| SCHEMBL2050032 | 0.87 | PARP1 (1.00) | PARP1PARP2PARP3TNKSPARP10 | |
| SCHEMBL2317217 | 0.87 | PARP1 (1.00) | PARP1PARP2PARP3TNKSPARP10 | |
| SCHEMBL2313547 | 0.87 | PARP1 (1.00) | PARP1PARP2PARP3TNKSPARP10 | |
| SCHEMBL2051171 | 0.87 | PARP1 (1.00) | PARP1PARP2PARP3TNKSPARP10 | |
| SCHEMBL29948048 | 0.87 | PARP1 (1.00) | PARP1PARP2PARP3TNKSPARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3241832-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | Medivation Technologies, Inc. (US) | 2017-11-08 | — | — | EP | claimed |
| US-9018201-B2 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency | Biomarin Pharmaceuticial Inc. (US) | 2015-04-28 | — | — | US | claimed |
| EP-2326650-B9 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | BIOMARIN PHARM INC (US) | 2014-09-10 | — | — | EP | claimed |
| US-20140066429-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) FOR USE IN TREATMENT OF DISEASES ASSOCIATED WITH A PTEN DEFICIENCY | BIOMARIN PHARMACEUTICAL INC. (US) | 2014-03-06 | — | — | US | claimed |
| EP-2326650-B1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | BIOMARIN PHARM INC (US) | 2014-02-26 | — | — | EP | claimed |
| US-8541403-B2 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency | BIOMARIN PHARMACEUTICAL INC. (US) | 2013-09-24 | — | — | US | claimed |
| US-8420650-B2 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) | BIOMARIN PHARMACEUTICAL INC. (US) | 2013-04-16 | — | — | US | claimed |
| EP-2531033-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) FOR USE IN TREATMENT OF DISEASES ASSOCIATED WITH A PTEN DEFICIENCY | BioMarin Pharmaceutical Inc. (US) | 2012-12-12 | — | — | EP | claimed |
| US-20110237581-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | MEDIVATION TECHNOLOGIES LLC | 2011-09-29 | — | — | US | claimed |
| WO-2011097334-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) FOR USE IN TREATMENT OF DISEASES ASSOCIATED WITH A PTEN DEFICIENCY | BIOMARIN PHARMACEUTICAL INC. (US) | 2011-08-11 | — | — | WO | claimed |
| US-20110190288-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) FOR USE IN TREATMENT OF DISEASES ASSOCIATED WITH A PTEN DEFICIENCY | MEDIVATION TECHNOLOGIES LLC | 2011-08-04 | — | — | US | claimed |
| US-20100035883-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2010-02-11 | — | — | US | claimed |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2022-09-20 | — | — | US | disclosed |
| US-11364241-B2 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) | MEDIVATION TECHNOLOGIES LLC (US) | 2022-06-21 | — | — | US | disclosed |
| US-20210069191-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | MEDIVATION TECHNOLOGIES LLC | 2021-03-11 | — | — | US | disclosed |
| US-10780088-B2 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) | MEDIVATION TECHNOLOGIES LLC (US) | 2020-09-22 | — | — | US | disclosed |
| US-20110190288-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) FOR USE IN TREATMENT OF DISEASES ASSOCIATED WITH A PTEN DEFICIENCY | MEDIVATION TECHNOLOGIES LLC | 2011-08-04 | — | — | US | disclosed |
| EP-2326650-A2 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | BioMarin Pharmaceutical Inc. (US) | 2011-06-01 | — | — | EP | disclosed |
| WO-2010017055-A2 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| US-20100035883-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10780088-B2 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) | PARP1, PARP2, PARP11 | PARP1 1/4885PARP2 2/4885PARP3 4/4885 |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DCK, CDC7, DNMT1 | PARP1 418/4885PARP2 422/4885PARP3 932/4885 |
| US-20110237581-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | PARP1, PARP2, PARP11 | PARP1 1/4885PARP2 2/4885PARP3 4/4885 |
| US-11364241-B2 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) | PARP1, PARP2, PARP11 | PARP1 1/4885PARP2 2/4885PARP3 4/4885 |
| US-20110190288-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) FOR USE IN TREATMENT OF DISEASES ASSOCIATED WITH A PTEN DEFICIENCY | PARP1, PARP2, PARP11 | PARP1 1/4885PARP2 2/4885PARP3 9/4885 |
| US-20100035883-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | PARP1, PARP2, PARP11 | PARP1 1/4885PARP2 2/4885PARP3 4/4885 |
| US-20140066429-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) FOR USE IN TREATMENT OF DISEASES ASSOCIATED WITH A PTEN DEFICIENCY | PARP1, PARP2, PARP11 | PARP1 1/4885PARP2 2/4885PARP3 9/4885 |
| US-20210069191-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | PARP1, PARP2, PARP11 | PARP1 1/4885PARP2 2/4885PARP3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.